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Adenovirus-mediated transfection of mouse cardiac
allografts with active human transforming growth
factor-beta 1 (TGF-b1) prolongs transplant survival pro-
vided that recipients are initially depleted of CD8+ T
cells. To test if graft survival was prolonged by per-
sistent TGF-b1 transgene expression, long-term trans-
fected allografts were re-transplanted into naı̈ve mice
that were transiently depleted of CD8+ T cells. Re-
transplanted allografts were acutely rejected, indicat-
ing that TGF-b1 transgene expression did not sup-
press effector cell function. We next asked whether
TGF-b1 gene transfer was associated with the develop-
ment of regulatory cells. When splenocytes obtained
from mice bearing long-term TGF-b1-transfected allo-
grafts were adoptively transferred into recipients of
non-transfected cardiac allografts, prolonged allograft
survival was observed, and increased levels of the reg-
ulatory T cell transcription factor Foxp3 were present.
To further test for regulation, differentiated effector
cells were obtained from mice that had rejected car-
diac allografts and were adoptively transferred into
mice bearing long-term TGF-b1 transfected cardiac al-
lografts. The effector cells failed to mediate rejection
in mice bearing TGF-b1-transfected allografts and we
observed a significant increase in intra-graft Foxp3
expression. These findings indicate that TGF-b1 gene
transfer allows for the development of regulatory cells
that control graft-reactive T cell responses once ther-
apeutic levels of the transgene product are no longer
produced.
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Introduction
Gene transfer of immunomodulatory agents into allografts
represents a clinically applicable approach to prolong trans-
plant survival (reviewed in 1,2). Since vascularized trans-
plants are routinely perfused at the time of organ harvest,
introduction of the transgene can be accomplished at this
time. It has been suggested that local secretion of solu-
ble transgene products after transfection results in high
concentrations of the immunosuppressive agent within
the micro-environment of the graft itself, thereby limit-
ing the deleterious effects of systemic immunosuppres-
sion. The use of adenoviral vectors allows efficient trans-
fection of quiescent cells (3,4), including the parenchymal
cells of solid organ transplants. However, anti-adenoviral
immune responses may result in inflammation and loss of
transgene expression in some transfected tissues (5–7).
We have demonstrated that although adenovirus-mediated
gene transfer of mouse cardiac grafts may induce an anti-
adenoviral immune response, this response ignores the
transfected cardiac graft, and transgene expression per-
sists without local inflammation (8). Hence, adenoviral vec-
tors represent an effective means of gene delivery into
cardiac transplants.
TGF-b has a broad range of anti-inflammatory properties
(9), including the inhibition of Th1 responses (10), E-selectin
expression by endothelial cells (11), and CTL development
(12). TGF-b also inhibits B cell proliferation and induces
apoptosis in B cells (13,14) and fully differentiated plasma
cells (9). Finally, TGF-b inhibits IFNc and inducible nitric
oxide synthase (iNOS) production, and increases expres-
sion of IL-1 receptor antagonist by activated macrophages
(9,15). Indeed, we and others have demonstrated that
adenovirus-mediated transfection with TGF-b1 (Ad-TGF-b
1) prolongs cardiac allograft survival (16–18). In our study
(18), transfection of cardiac allografts, with adenovirus en-
coding the active form of human TGF-b1, promoted long-
term cardiac allograft survival provided that recipients were
transiently depleted of CD8+ cells at the time of trans-
plantation. Th1 priming in the spleen and alloantibody re-
sponses in recipients were ablated by TGF-b1 transfec-
tion of the allograft, demonstrating systemic effects on
the immune response (18), yet precursor graft-reactive
T cells were readily detectable. The mechanism by which
TGFb1 gene transfer promotes long-term graft survival and
controls graft-reactive precursor cells is not known. For
example, Ad-TGF-b1 transfection of grafts results in
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expression of TGF-b1 mRNA for at least 60 days post-
transplant (18), suggesting that persistent transgene ex-
pression may continuously control immune responses. Yet,
the systemic nature of the immunosuppression suggests
that mechanisms other than local TGF-b1 expression may
be operative.
Our previous study (18) demonstrated the need for tran-
sient depletion of CD8+ T cells for TGF-b1 gene transfer
to mediate these immunosuppressive effects. However,
graft-reactive CD8+ T cell responses were kept in check
once these cells re-populated the periphery. A growing
body of evidence indicates that CD8+ T cells are more diffi-
cult to control than are their CD4+ counterparts (reviewed
in 19). Furthermore, it is well documented that CD4+
T cells may acquire T regulatory (Treg) function in the trans-
plant setting (reviewed in 20). These findings are in keeping
with the notion that regulatory cells develop with time in re-
cipients of TGF-b1-transfected allografts. The current study
examines the potential role of persistent transgene ex-
pression and regulatory cells in the control of graft-reactive
T cell responses following TGF-b1 gene transfer. Our find-
ings support a role for regulatory cells in promoting graft




Female C57BL/6 (H-2b), and BALB/c (H-2d) mice between 6 and 12 weeks of
age were obtained from Charles River Laboratories (Raleigh, NC). C3H/HeN
(H-2k) mice were obtained from Harlan (Indianapolis, IN).
TGF- b1 encoding adenovirus
Ad-TGF-b1 consists of the cDNA encoding the active form of human TGF-b1
under the control of an RSV promoter placed in a replication-defective E1-
and E3- deleted serotype 5 adenovirus vector (21). The TGF-b1 gene was
cloned into the Not 1 site of the proviral plasmid, pAdRSV. Recombinant
adenoviral clones were generated as described (22) and were subjected to
two rounds of plaque purification prior to large-scale expansion and purifica-
tion over cesium chloride gradients. Stocks of Ad-TGFb1 were produced for
in vivo use in the Vector Core at the University of Michigan Medical Center.
Each stock of Ad-TGF-b1 was assessed for the ability to encode bioactive
TGF-b1 by transfecting human kidney 293 cells (MOI = 100) and quantifying
active TGF-b1 in the supernatant using the CCL4 mink lung epithelial cell
assay (23).
TGF- b1 transfection of vascularized cardiac transplants
Prior to in situ perfusion of the donor heart, the left superior vena cava and
the distal aorta were ligated to retain the perfusate. The aorta was then held
in position by suture to facilitate perfusion using a syringe with a 30-gauge
needle. The donor heart was flushed with 400 lL of heparin (250 U/mL),
then perfused with 200 lL of lactated Ringer’s solution containing adenovi-
ral vectors (5 × 108 pfu). Following perfusion, donor grafts were harvested
and placed in iced Ringer’s for approximately 1 h prior to transplantation.
Transfection occurs during the 1-h period of cold storage, which mimics the
cold ischemic time human organs experience during transport. The trans-
fected grafts were anastomosed to the great vessels in the abdomen as
described previously (24,25). Briefly, the donor aorta and pulmonary artery
were anastomosed end-to-side with the recipient’s abdominal aorta and in-
ferior vena cava. In this model, the transplanted heart is perfused with the
recipient mouse’s blood and resumes contraction. Transplant function was
monitored by daily abdominal palpation.
Re-transplantation of cardiac allografts
TGF-b1-transfected cardiac allografts were removed from primary allograft
recipients at 50 days post-transplant and re-transplanted into secondary re-
cipients as previously described (25). Briefly, the primary allograft was care-
fully dissected from surrounding adhesions using a fine-tip cautery, vessels
attached to the primary allograft were ligated, and the heart was removed
from the primary recipient and transplanted into the secondary recipient via
end-to-side anastomoses of transplant-associated aorta and vena cava to re-
cipient aorta and vena cava. The re-transplanted hearts were then perfused
with the recipient mouse’s blood and resumed contraction spontaneously.
Graft function was monitored by daily abdominal palpation.
In vivo depletion of CD8+ T cells
C57BL/6 mice were injected i.p. with 1 mg of anti-CD8 mAb (hybridoma
2.43, purified by Ligocyte Pharmaceuticals, Inc., Bozeman, MT) 1 day prior
to transplantation with BALB/c cardiac allografts. An additional 1 mg was
injected the day of transplantation, and on day +5, following transplantation.
This protocol results in transient depletion of CD8+ cells, which re-populate
the periphery approximately 30 days post-transplant (18).
Adoptive transfer of splenocytes
To test for the presence of regulatory cells, C57BL/6 recipients of BALB/c
TGF-b1-transfected allografts were sacrificed at day 50 post-transplant, and
the spleens were harvested. For isolation of differentiated effector spleno-
cytes, spleens were harvested from unmodified C57BL/6 recipients of
BALB/c cardiac allografts at 10 days post-transplant, once the recipients
had actively rejected their transplants. Spleens were processed through
wire mesh, and splenocytes were filtered through a 30-lm pore size ny-
lon mesh and re-suspended in sterile PBS. For adoptive transfer, 5 × 107
splenocytes in 200 lL were injected via the tail vein into recipients at the
indicated times.
Qualitative assessment of Foxp3 mRNA levels
RNA was isolated by phenol-chloroform extraction, and cDNA generated
by a standard reverse transcription protocol. Foxp3 primers were designed
using Primer Premier 5.0 software (Biosoft International, Palo Alto, CA)
and were sense 5′ CCAAGGTGAGCGAGTGTC and anti-sense 5′ AAG-
GCAGAGTCAGGAGAAGT. Control GAPDH primers were designed using
Primer 2 software (Scientific and Educational Software, State Line, PA) and
were sense 5′ CTGGTGCTGAGTATGTCGTG and anti-sense 5′ CAGTCTTCT-
GAGTGGCAGTG. Real-time PCR was performed on a Cepheid Smart Cy-
cler c© System (Cepheid, Sunnyvale, CA) and primer binding to DNA was
detected by SYBER Green ITM dye (Roche, Indianapolis, IN). Relative quan-
tification of Foxp3 expression was obtained by subtracting the cycle thresh-
old (Ct), or the point above baseline at which fluorescence is detected, of
GAPDH from the Ct of Foxp3. The resulting difference in the cycle number
is the exponent of the base 2 representing the fold difference between
Foxp3 and GAPDH in cardiac cDNA samples.
Statistical analysis
Results were analyzed using a Fischer’s PLSD test and p-values ≤0.05 were
considered statistically different.
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Results
Prolonged TGF-b1 transgene expression does not
prevent rejection of re-transplanted cardiac allografts
We have previously reported that TGF-b1 transgene ex-
pression persists for at least 60 days in this system
(18). While transgene expression decreases with time
(8), it is not known whether transgene expression per-
sists at therapeutic levels. Therefore, we determined
whether persistent transgene expression in mice bearing
long-term TGF-b1-transfected cardiac allografts contributed
to transplant survival. To test this possibility, BALB/c
TGF-b1-transfected cardiac allografts were removed from
their original C57BL/6 recipients at day 50 post-transplant
and re-transplanted into secondary C57BL/6 recipients
that were transiently depleted of CD8+ cells. Allograft
function was monitored in these secondary recipients.
Re-transplantation of BALB/c TGF-b1-transfected hearts
into secondary recipients resulted in acute rejection (Fig-
ure 1). However, rejection of these re-transplanted TGF-b
1-transfected allografts was slightly delayed when com-
pared to BALB/c cardiac grafts that were transplanted
into BALB/c primary recipients and then re-transplanted
into CD8-depleted C57BL/6 secondary recipients. This sug-
gests that persistent low-level TGF-b1 transgene expres-
sion may contribute to allograft survival, although this level
of transgene expression is inadequate to completely sup-
press the rejection response. As a control for the success
of the re-transplantation technique, syngeneic C57BL/6
hearts were transplanted into primary C57BL/6 hosts and
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Figure 1: Transfection of cardiac allografts with TGF-b1 does
not confer survival after re-transplantation. TGF-b1-transfected
cardiac allografts were removed from C57BL/6 primary allograft re-
cipients at day 50 post-transplant and re-transplanted into C57BL/6
secondary allograft recipients that were transiently depleted of
CD8+ T cells. Time of rejection was compared to BALB/c syn-
geneic grafts removed from BALB/c primary recipients and re-
transplanted into C57BL/6 secondary recipients. As controls for
the success of the re-transplantation procedure BALB/c syngeneic
transplants were removed from BALB/c primary recipients at day
50 post-transplant and re-transplanted into BALB/c secondary re-
cipients. Graft function was monitored by daily palpation, and the
time the transplant stopped beating was recorded as the day of
rejection.
hosts. These re-transplanted syngeneic grafts continued to
function normally until the termination of the experiment.
Together, our results indicate that expression of TGF-b1 in
the re-transplanted hearts had fallen below the therapeutic
threshold required for immunosuppression, and that these
long-term TGF-b1-transfected cardiac allografts retain their
immunogenicity.
TGF-b1 transfection is associated with the
development of regulatory cells
The fact that persistent transgene expression did not pre-
vent rejection of re-transplanted allografts suggested that
other mechanisms were operative in preventing graft-
reactive T cell responses. To test for potential regulatory
cell activity in this setting, splenocytes were obtained from
mice bearing TGF-b1-transfected allografts at day 50 post-
transplant and adoptively transferred into C57BL/6 mice
transiently depleted of CD8+ cells. These mice were trans-
planted with unmodified BALB/c cardiac allografts one day
after the adoptive transfer of cells. Transfer of splenocytes
from mice bearing long-term TGF-b1-transfected allografts
resulted in prolonged survival of unmodified BALB/c car-
diac allografts (Allo TGF-b; Figure 2), indicating that regu-
latory cells were present in the transferred splenocytes.
In addition, splenocytes transferred from mice bearing
long-term syngeneic allografts expressing TGF-b1 did not
prolong allograft survival in CD8-depleted recipients (Syn
TGF-b; Figure 2), indicating that regulatory cells were in-
duced only in the presence of alloantigen and TGF-b1 trans-
fection. To assess regulatory cell specificity, splenocytes
from mice bearing long-term TGF-b1-transfected BALB/c
allografts were transferred into C57BL/6 mice that were
Figure 2: Adoptive transfer of splenocytes from mice bear-
ing long-term TGF-b1-transfected allografts prolongs survival
of unmodified cardiac allografts. Splenocytes were harvested
at day 50 post-transplant from C57BL/6 mice bearing TGF-b1-
transfected BALB/c cardiac allografts (Allo TGF-b). Control spleno-
cytes were harvested at day 50 post-transplant from C57BL/6
mice bearing TGF-b1-transfected syngeneic allografts (Syn TGF-
b). Naı̈ve mice were injected i.p. with 1 mg anti-CD8 mAb on days
-2 and -1 relative to splenocyte adoptive transfer (5 × 107 cells
i.v.) and then were transplanted with unmodified BALB/c (B6 anti-
BALB/c) or third-party C3H (B6 anti-C3H) cardiac allografts the day
after adoptive transfer. Graft function was monitored by daily pal-
pation and the time the transplant stopped beating was recorded
as the day of rejection.
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depleted of CD8+ cells and transplanted with third-party
C3H allografts (Allo TGF-b → B6 anti-C3H). Survival of
these third-party allografts was slightly, but not statistically
prolonged, possibly reflecting a cross-reactivity between
BALB/c and C3H alloantigens (26). Indeed, histologic as-
sessment of third-party grafts that experienced delayed
rejection revealed a less intense infiltrate and more pre-
served cardiac myocytes when compared to rejected con-
trol grafts (Syn TGF-b → B6 anti-BALB/c) (data not shown).
Regulatory cells associated with TGF-b1 gene transfer
prevent rejection mediated by effector cells
Since regulatory cells associated with TGF-b1 gene transfer
were capable of suppressing the initial immune response
to a transplanted cardiac allograft, we next asked whether
these cells could control rejection responses mediated
by differentiated effector cells. To this end, we isolated
splenocytes from unmodified C57BL/6 mice that had re-
jected BALB/c cardiac allografts, and adoptively transferred
these splenocytes into recipients of TGF-b1-transfected al-
lografts at day 50 post-transplant. Adoptive transfer of ef-
fector cells failed to induce rejection of TGF-b1-transfected
allografts, and these grafts continued to function until the
termination of the experiment (Figure 3). As a positive con-
trol for effector cell function, these cells were injected into





Figure 3: Differentiated effector cells are incapable of mediat-
ing graft rejection in mice bearing day-50 TGF-b1-transfected
allografts. C57BL/6 recipients of TGF-b1-transfected allografts
were transiently depleted of CD8+ T cells. At day 50 post-
transplant, recipients were injected with 5 × 107 effector spleno-
cytes isolated on day 10 from C57BL/6 recipients that had acutely
rejected BALB/c cardiac allografts. As controls, C57BL/6 SCID re-
cipients of BALB/c allografts were also injected with effector cells.
Graft function was monitored by daily palpation and the day of re-
jection was recorded at the time the transplant stopped beating.
Results are recorded as the day post-effector cell transfer that
transplant function ceased.
acute rejection by day 10 post-adoptive transfer (Figure 3).
It should be noted that the transferred effector cells in-
cluded CD8+, as well as CD4+ effector T cells, indicating
that TGF-b1 gene transfer was effective against CD8+ cells
in this context.
Regulatory cells are present in cardiac allografts after
cell transfer
Recent studies have shown that TGF-b-dependent regula-
tory cells can be identified in graft tissue in mice tolerating
allografts (27). To test for the presence of regulatory cells
in heart allografts in our recipient mice, we used quantita-
tive real-time RT PCR to determine the relative intra-graft
expression of Foxp3, which has been identified as a tran-
scription factor essential for the development and function
of CD4+/CD25+ Treg (28,29). Levels of Foxp3 expression
varied in long-term TGF-b1-transfected allografts, although
the average relative expression in TGF-b1-transfected al-
lografts was greater than the expression in syngeneic al-
lografts also expressing TGF-b1 (Figure 4, comparison 1).
More important, grafts in mice that received splenocytes
from recipients of TGF-b1-transfected allografts (Allo TGF-
b trans; Figure 4) showed significantly greater levels of
Foxp3 expression (p = 0.03) than rejected grafts from recip-
ients that received splenocytes from mice bearing TGF-b1-
transfected syngeneic allografts (Syn TGF-b trans, Figure 4,
comparison 2), suggesting that the transferred regulatory
cells trafficked to the allograft. We also assessed the pres-
ence of regulatory cells in the TGF-b1-transfected grafts
of mice that received differentiated effector cells. Grafts
from these recipients also showed a significant increase in
Foxp3 expression when compared with grafts from SCID
recipients of adoptively transferred effector cells (p = 0.01;
Figure 4, comparison 3). Together, these results suggest
that TGF-b1 gene transfer associated regulatory cells are
capable of migrating to cardiac allografts and preventing
allograft rejection.
Discussion
We have previously reported that adenovirus-mediated
transfection of cardiac allografts with the active form of
TGF-b1 is effective in preventing graft-reactive T cell prim-
ing and promoting graft acceptance provided that CD8+
T cells are transiently depleted (18). However, precursor
graft-reactive cells re-appear as CD8+ cells re-populate the
periphery, but these cells are maintained in a quiescent
state. The current study evaluated mechanisms involved
in preventing the activation of these graft-reactive precur-
sor cells. At least two possibilities come to mind: first, it
is possible that persistent TGF-b1 transgene expression
continues to suppress the activation of quiescent precur-
sor cells. Indeed, we have found that adenoviral-mediated
transfection of cardiac transplants results in transgene ex-
pression for at least 60 days (8,18), albeit at lower lev-
els than that observed during the early post-transplant
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Figure 4: Relative intra-graft expression of Foxp3 is increased
by transfection with TGF-b1. Total RNA was isolated from car-
diac grafts under the following conditions: Comparison 1: Cardiac
grafts were harvested on day 50 from C57BL/6 mice transiently de-
pleted of CD8+ T cells that received TGF-b1 transfected C57BL/6
grafts (syn TGF-b), or TGF-b1-transfected BALB/c grafts (allo TGF-
b). Comparison 2: Grafts were harvested from CD8-depleted re-
cipients of unmodified BALB/c allografts that received spleno-
cytes from long-term recipients of C57BL/6 TGF-b1-transfected
allografts (syn TGF-b trans) or from long-term recipients of BALB/c
TGF-b1-transfected allografts (allo TGF-b trans). Grafts were har-
vested at the time of transplant rejection (syn TGF-b trans, see Fig-
ure 2) or at day 35 post-transplant (allo TGF-b trans). Comparison 3:
Grafts were harvested from SCID recipients of TGF-b1-transfected
BALB/c grafts that received differentiated effector cells (SCID +
eff) or from long-term C57BL/6 recipients of TGF-b1-transfected
BALB/c allografts that received differentiated effector cells (allo
TGF-b + eff). Grafts were harvested at the time of transplant re-
jection (SCID + eff, see Figure 3) or at day 35 post-effector cell
transfer (allo TGF-b + eff). Relative levels of Foxp3 expression
were quantified as described in materials and methods. The aver-
age relative expression of Foxp3 for each experimental group is
indicated by horizontal lines, and the p-values between groups are
reported.
period (8). To test whether the level of TGF-b1 transgene
expression retained the ability to prevent the rejection re-
sponse, we re-transplanted accepted TGF-b1-transfected
cardiac allografts into naı̈ve mice that were transiently de-
pleted of CD8+ cells (Figure 1). These grafts were acutely
rejected, indicating that the level of TGF-b1 expression had
fallen below the threshold required to subvert the rejection
response mounted by the secondary allograft recipients. It
is possible that the re-transplantation procedure and as-
sociated ischemia may have induced pro-inflammatory cy-
tokines such as TNFa, which Bromberg’s group has shown
can inhibit viral promoter driven transgene expression (30).
However, it should be noted that the initial transplant pro-
cedure would also subject the graft to similar inflammatory
processes, yet the level of TGF-b1 transgene expression is
sufficient to inhibit the rejection response in the primary
allograft recipient. This indicates that TGF-b1 transgene ex-
pression falls below a therapeutic threshold with time fol-
lowing transplantation. Rejection of these re-transplanted
allografts also illustrates that these accepted grafts main-
tain their immunogenicity, thereby further supporting the
notion that acceptance of TGF-b1-transfected allografts is
an active process.
Since persistent TGF-b1 transgene expression did not ap-
pear to be the primary factor responsible for long-term al-
lograft acceptance, a second possibility is that active reg-
ulation participates in graft acceptance. Indeed, several
studies have demonstrated that TGF-b plays an important
role in the induction of Treg (27,31,32). To test the effect
of TGF-b1 secreted by the graft on systemic alloimmune
responses, we isolated splenocytes from mice bearing
long-term TGF-b1-transfected grafts and adoptively trans-
ferred these cells into mice that were transiently depleted
of CD8+ cells and received unmodified allografts. Cells
from recipients of TGF-b1-transfected allografts, but not
TGF-b1-transfected syngeneic grafts, prevented acute re-
jection (Figure 2). These results indicate that the presence
of both alloantigen and TGF-b1 were required to induce
regulation. Interestingly, this adoptive transfer approach re-
vealed a possible third-party cross-reactivity of these reg-
ulatory cells in that they promoted a degree of protection
when transferred into third-party allograft recipients. The
presence of these regulatory cells was further illustrated
by the experiments depicted in Figure 3, where differen-
tiated effector cells transferred into mice bearing TGF-b1-
transfected allografts could not induce rejection. Together,
these results demonstrate that a population of regulatory
cells develops when TGF-b1 is secreted within the allograft.
To verify that regulatory cells were functioning in our sys-
tem, we assessed the levels of Foxp3 expressed within
the allograft (Figure 4). Foxp3 has been identified as the
transcription factor present in regulatory, but not activated
CD4+/CD25+ T cells (28), and is currently considered the
most reliable marker for Treg. Therefore, increased Foxp3
expression within the graft would reflect the presence of
Treg that have trafficked to the allograft where they may
mediate regulatory function. We have noted that levels
of Foxp3 expression in the spleen are not informative,
as naı̈ve, non-transfected mice have detectable levels of
Foxp3 expression due to the presence of endogenous Treg
(data not shown). We first determined the relative expres-
sion of Foxp3 in long-term allogeneic TGF-b1-transfected
grafts versus syngeneic TGF-b1-transfected grafts (Fig-
ure 4, comparison 1). Variable levels of Foxp3 were ex-
pressed in accepted TGF-b1-transfected allografts with 5 of
12 expressing higher levels than TGF-b1-transfected syn-
geneic grafts. It should be noted that only low levels of
Foxp3 were expressed in TGF-b1-transfected syngeneic
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grafts, reflecting the inability of splenocytes obtained from
these mice to adoptively transfer immunosuppression (Fig-
ure 2). The variability in the levels of Foxp3 within accepted
allografts may reflect trafficking of Treg between the graft
and lymphoid tissues. Hence, regulatory cells may traffic
to the graft on an as-needed basis. This possibility is sup-
ported by the observation that adoptive transfer of spleno-
cytes from mice bearing long-term TGF-b1-transfected allo-
grafts, which promoted graft survival (Figure 2), coincided
with increased Foxp3 expression within functioning grafts
in splenocyte recipients (Figure 4, comparison 2). Further-
more, adoptive transfer of effector cells into mice bearing
long-term TGF-b1-transfected allografts failed to induce re-
jection (Figure 3), a result which was reflected by increased
Foxp3 expression within the graft (Figure 4, comparison 3).
The trafficking capacity of Treg has been recently demon-
strated by Fu et al. (33), who reported that Treg expressing
the peripheral lymph node homing receptor, CD62L, mi-
grate to lymph nodes and are more effective at suppress-
ing immune responses than are Treg that express low levels
of CD62L. Our adoptive transfer studies (Figure 4) provide
further evidence for regulatory cell migration to allografts.
Prolonged survival of TGF-b1-transfected allografts and the
generation of regulatory cells in this system requires that
the allograft recipient be transiently depleted of CD8+
T cells (18). In addition, the ability of splenocytes obtained
from mice bearing long-term TGF-b1-transfected allografts
to adoptively transfer suppression is dependent upon ini-
tial depletion of recipient CD8 cells (data not shown). Other
studies have shown that Treg are capable of suppressing
CD8+ T cells both in vitro (34) and in vivo in transplant
models (35,36). It should be noted that these studies em-
ployed transgenic TCR CD8+ T cells that respond to a sin-
gle peptide, rather than the polyclonal CD8+ T cell popula-
tion that is mobilized in our system. Using this cardiac allo-
graft model, we (37) and others (38) have reported that the
development of regulatory cells following anti-CD40L ther-
apy does not require transient depletion of CD8+ T cells.
This may be due to the sensitivity of CD4+ versus CD8+
T cells to TGF-b and other immunosuppressive agents (re-
viewed in 19). Hence, induction of regulatory cells follow-
ing TGF-b1 gene transfer appears to have differential re-
quirements when compared to other transplant settings
(35–38). For example, production of IFNc by CD4+ T cells
is more dependent upon IL-12 (39), Stat 4 (40), and the Th1
transcription factor T-bet (41) than is production by their
CD8+ counterparts. Since TGF-b inhibits T-bet expression
(42), which is required for IFNc production by CD4+ but
not CD8+ T cells (41), it makes biologic sense that CD8+
T cells would be less susceptible than CD4+ T cells to
TGF-b1 gene transfer. It should be noted that CD8+
T cells have an additional transcription factor, Eomesoder-
min, which facilitates T-bet-independent IFNc production
(43). Interestingly, adoptive transfer of differentiated ef-
fector splenocytes (which contain activated CD8+ cells)
did not result in rejection of TGF-b1-transfected grafts (Fig-
ure 3). In this instance, Foxp3 expression was increased
in the TGF-b1-transfected graft (Figure 4) and regulatory
cells appeared to be capable of controlling the primed
CD8+ response. This may reflect the fact that Foxp3-
expressing regulatory cells have already developed in long-
term recipients of TGF-b1-transfected allografts and are
present in sufficient numbers to control the CD8+ T cell
response.
In summary, this study has shown that adenoviral-
mediated gene transfer of TGF-b1 is associated with the
development of regulatory cells which traffic to the graft
and are capable of controlling precursor as well as differ-
entiated graft-reactive T cells. We suggest that these regu-
latory cells develop with time under the cover of transient
CD8+ T cell depletion and intra-graft TGF-b1 expression,
which wanes with time. To our knowledge, this is the first
report of an immunosuppressive cytokine gene therapy
regimen that facilitates the development of regulatory cells
which continue to control the rejection response once ther-
apeutic levels of the transgene product have subsided.
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